COVID-19 Vaccines Concept

subject area of

• (Mis)Communication of COVID‐19 vaccine benefits and harms  Academic Article
• A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval  Academic Article
• A fast, efficient, and scalable method for purifying recombinant SARS-CoV-2 spike protein  Academic Article
• A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2  Academic Article
• A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial  Academic Article
• A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial  Academic Article
• AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update  Academic Article
• Acceptance of COVID-19 Vaccination Among Health System Personnel  Academic Article
• Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia  Academic Article
• Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia  Academic Article
• Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein  Academic Article
• Applied behavioral economics and public health policies: Historical precedence and translational promise  Academic Article
• Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination?  Academic Article
• BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan  Academic Article
• Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study  Academic Article
• Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey  Academic Article
• COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death  Academic Article
• COVID-19 Vaccine Intentions and Perceptions Among Public School Staff of the Greater Vancouver Metropolitan Area, British Columbia, Canada  Academic Article
• COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects  Academic Article
• COVID-19 boosters in rich nations will delay vaccines for all  Academic Article
• COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study  Academic Article
• COVID-19 vaccines and kidney disease  Academic Article
• COVID-19 vaccines for Palestinians  Academic Article
• COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development  Academic Article
• Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases  Academic Article
• Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study  Academic Article
• Commentary on Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection  Academic Article
• Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273  Academic Article
• Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study  Academic Article
• Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV  Academic Article
• Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals  Academic Article
• Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination  Academic Article
• Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.  Academic Article
• Demographic characteristics, outcomes and experience of patients using virtual urgent care services from 14 emergency department led sites in Ontario  Academic Article
• Diagnostic accuracy of Augurix COVID‐19 IgG serology rapid test  Academic Article
• Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID ‐19 vaccines: A systematic review and meta‐analysis  Academic Article
• Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia  Academic Article
• Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey  Academic Article
• Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies  Academic Article
• Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study  Academic Article
• Emergency use authorisation for COVID-19 vaccines: lessons from Ebola  Academic Article
• Ending COVID-19: progress and gaps in research—highlights of the July 2020 GloPID-R COVID-19 Research Synergies Meetings  Academic Article
• Epidemiology of VITT.  Academic Article
• Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes  Academic Article
• Evaluating COVID-19 vaccines in the real world  Academic Article
• Evaluation of the Performance of a Multiplexed Serological Assay in the Detection of SARS-CoV-2 Infections in a Predominantly Vaccinated Population  Academic Article
• Evolutionary trajectory of SARS-CoV-2 and emerging variants  Academic Article
• Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity  Academic Article
• Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19  Academic Article
• Factors Associated With Willingness to Receive a COVID-19 Vaccine Among 23,819 Adults Aged 50 Years or Older: An Analysis of the Canadian Longitudinal Study on Aging  Academic Article
• Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2  Academic Article
• Global inequity creates local insufficiency: A qualitative study of COVID-19 vaccine implementation challenges in low-and-middle-income countries  Academic Article
• Guidelines for the prevention and management of children and adolescents with COVID-19  Academic Article
• High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination  Academic Article
• Immunological considerations for COVID-19 vaccine strategies  Academic Article
• In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)  Academic Article
• In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose  Academic Article
• In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose  Academic Article
• Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method  Academic Article
• Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA)  Academic Article
• Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada  Academic Article
• Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022  Academic Article
• Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group  Academic Article
• Kukaa Salama (Staying Safe): study protocol for a pre/post-trial of an interactive mHealth intervention for increasing COVID-19 prevention practices with urban refugee youth in Kampala, Uganda  Academic Article
• Lessons from vaccine-induced immune thrombotic thrombocytopenia  Academic Article
• Lien possible entre rhabdomyolyse et vaccin anti-SRAS-CoV-2 à ARNm chez une patiente porteuse d’une mutation du gène RYR1  Academic Article
• Management of anaphylaxis due to COVID‐19 vaccines in the elderly  Academic Article
• Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study  Academic Article
• Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial  Academic Article
• No apparent association between mRNA COVID-19 vaccination and venous thromboembolism  Academic Article
• Pathogenesis, immunology, and immune‐targeted management of the multisystem inflammatory syndrome in children (MIS‐C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper  Academic Article
• Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Detect a SARS-CoV-2 Antibody Response  Academic Article
• Pivoting data and analytic capacity to support Ontario’s COVID-19 response  Academic Article
• Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group  Academic Article
• Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B  Academic Article
• Priority setting during the COVID-19 pandemic: going beyond vaccines  Academic Article
• Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey  Academic Article
• R&D during public health emergencies: the value(s) of trust, governance and collaboration  Academic Article
• Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories  Academic Article
• Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia  Academic Article
• Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: Communication from the ISTH SSC Subcommittee on Platelet Immunology  Academic Article
• Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”  Academic Article
• Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2  Academic Article
• Risk of SARS-CoV-2 infection following initial COVID-19 vaccination: Population-based cohort study  Academic Article
• Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines  Academic Article
• SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia  Academic Article
• SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection  Academic Article
• Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples  Academic Article
• South Asian Youth as Vaccine Agents of Change (SAY-VAC): evaluation of a public health programme to mobilise and empower South Asian youth to foster COVID-19 vaccine-related evidence-based dialogue in the Greater Toronto and Hamilton Area, Canada  Academic Article
• Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study  Academic Article
• Supporting the pandemic response and timely access to COVID-19 vaccines: a case for stronger priority setting and health system governance in Nigeria  Academic Article
• The COVID ‐19 pandemic and its consequences for chronic pain: a narrative review  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020  Academic Article
• The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021  Academic Article
• The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose  Academic Article
• The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper  Academic Article
• The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis  Academic Article
• The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach  Academic Article
• The Role of a Resilient Information Infrastructure in COVID-19 Vaccine Uptake in Ontario  Academic Article
• The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia  Academic Article
• The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials  Academic Article
• The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic  Academic Article
• Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords  Academic Article
• Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination  Academic Article
• Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum  Academic Article
• Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial  Academic Article
• Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination  Academic Article
• Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination  Academic Article
• Transmission dynamics are crucial to COVID-19 vaccination policy  Academic Article
• Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)  Academic Article
• Unnecessary hesitancy on human vaccine tests—Response  Academic Article
• Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021  Academic Article
• Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders  Academic Article
• Vaccine-induced immune thrombotic thrombocytopenia  Academic Article
• Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil  Academic Article
• Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials  Academic Article
• Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)  Academic Article
• Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources  Academic Article
• WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations  Academic Article
• What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2)  Academic Article